Evidence map›Paper›PMID 41551531›Full record

ArticleWorld journal of gastroenterology2026

Peroxiredoxin 1, pyroptosis, and the emerging frontier in colorectal cancer therapy.

Dharmendra Kumar Maurya

Abstract readEditorial
In one paragraph

Article in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Dharmendra Kumar MauryaRadiation Biology & Health Sciences Division, Bhabha Atomic Research Centre, Mumbai 400085, Maharashtra, India. dkmaurya@barc.gov.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) remains a major global health challenge, with high recurrence and mortality despite advances in surgery, chemotherapy, and immunotherapy. The study by He

Indexed as

Colorectal NeoplasmsPeroxiredoxinsPyroptosisAnimalsAntineoplastic AgentsCaspase 1HumansInflammasomesMiceNLR Family, Pyrin Domain-Containing 3 ProteinSignal TransductionAntineoplastic AgentsCaspase 1InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinPeroxiredoxinsPRDX1 protein, humanColorectal cancerDamage-associated molecular patternImmunogenic cell deathPeroxiredoxin 1Pyroptosis

Identifiers

PMID41551531
PMCPMC12809155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.